Patients with coeliac disease are at greater risk than the general population of developing neoplasms, principally malignant lymphomas, but also gastrointestinal malignancies.'l In November 1978, in order to establish which non-lymphomatous malignancies complicate coeliac disease and to determine the histological nature of the associated lymphoma, a national collaborative study of coeliac patients with malignancy was set up at the Clinical Research Centre.
The results, based on analysis of 235 patients, showed that the predominant type of malignant lymphoma was a malignant histiocytosis, and that amongst the gastrointestinal malignancies, small intestinal adenocarcinomas and oesophageal carcinomas were the most frequent.3
Although previous studies of HLA associations with malignancies have yielded essentially negative results,4 coeliac disease is strongly associated with certain HLA antigens, primarily HLA DR 3, and in some populations HLA DR 7.5 The establishment of the register provided the opportunity to carry out HLA-A, B, C and DR antigen typing on a group of coeliac patients with malignancy. The strength of association with malignancy was estimated for each specificity by the relative risk calculated as Woolf's cross-product ratio with Haldane's correction applied whenever one of the compared values was null.12 The significance of association was evaluated by Fisher's exact test, one sided. Probability values were not corrected for the number of comparisons made, but because of the number of such comparisons it was decided to regard as significant only values of p<001.
Results
No significant differences in antigen frequencies were found between the patients with and without malignancy ( Table 3) . Similarly comparison between the 12 patients with malignant histiocytosis and those without malignancy failed to reveal any significant differences.
Discussion
The coeliac patients with malignancy in the present study were those still alive in 1979 or who were diagnosed between 1979 and the end of March 1981. This has resulted in the sample containing proportionately fewer individuals with malignant lymphomas and proportionately more with gastrointestinal or other malignancies than in the entire national study. Nevertheless, in patients in the sample the predominant type of malignant lymphoma, malignant histiocytosis (Table 1) was the same as among patients from whom blood samples were not obtained, and patients with small intestinal adenocarcinoma and oesophageal carcinoma were represented. Thus patients in this study are reasonably representative of coeliac patients with malignancy as indicated by those included in the national collaborative study. The principal findings were that there were no significant differences in antigen frequencies between coeliac patients with and without malignancy or between the subgroup of patients with malignant histiocytosis and those without malignancy. This agrees with the results of a recently published study from the west of Ireland The negative results of this study do not exclude the involvement of HLA factors in the development of malignancy in coeliac patients. In the present study 94 (93.1%) of the 101 coeliac patients were positive for HLA DR 3 showing that the strong association with this antigen found in other coeliac populations studied is also found in Britain. Further, 38 (37.6%) were positive for HLA DR 7, although the significance of this is uncertain without a sufficiently large and comparable group of healthy individuals without coeliac disease for comparison. Perhaps it is the possession of one or both of these antigens or of a genetic factor closely linked to those determining them which determines the response of a coeliac patient to an environmental factor, perhaps even gluten itself, and results in the development of malignancy. 
